Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotec) has submitted its monthly return for the period ended 31 October 2026, confirming a stable capital structure and outlining its latest share repurchase position.

The company’s registered share capital remained unchanged at 228.83 million shares (par value: RMB 1.00 each), split into 34.78 million H shares listed in Hong Kong and 194.05 million A shares listed on Shanghai’s STAR Market (stock code 688366).

Issued share volumes were also steady during the month: • H-share count: 34.78 million shares in issue; no treasury shares. • A-share count: 190.20 million shares in issue and 3.85 million shares held in treasury.

Haohai Biotec reiterated that 1.14 million H shares repurchased between May and October 2026 remain in treasury pending formal cancellation. No new shares were issued, and no options, warrants or convertible securities were outstanding or exercised during the month.

The board confirmed compliance with Hong Kong’s minimum public-float requirement of 5 % for PRC issuers and attested that all regulatory obligations, including filings and settlement of consideration for share repurchases, have been met.